Pharmacologic treatments for covid-19 patients

Ruxolitinib vs Placebo


Hospitalized patients

Forest plots
(last update: 2022-05-16)

Summary of findings
(last update: 2022-09-27)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=750

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
NCT04377620
RUXCOVID-DEVENT
Incyte Corporation, Unpublished, 2022
Full text
Private

Ruxolitinib 5mg

Ruxolitinib 15mg

Placebo

RCT Patients with confirmed COVID-19 (critical) admitted to 33 centers in Russia and the USA N=211
Low
Details

Full description

NCT04362137; EudraCT 2020-001662-11
RUXCOVID
Han MK, Lancet Rheumatol, 2022
Full text
Full text
Commentary
Private

Ruxolitinib

Placebo

RCT Patients with confirmed COVID-19 (mild-moderate-severe) admitted to 61 centers in 12 countries (UK, US, Spain, Germany, Russia, Brazil, Argentina, Colombia, Peru, Mexico, France, Turkey). N=432
Some concerns
Details

Full description